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Abstract
Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative disease of the central nervous system with 
unknown etiology. Currently approved disease-modifying treatment modalities are immunomodulatory or immunosuppres-
sive. While the applied drugs reduce the frequency and severity of the attacks, their efficacy to regenerate myelin membranes 
and to halt disease progression is limited. To achieve such therapeutic aims, understanding biological mechanisms of remy-
elination and identifying factors that interfere with remyelination in MS can give respective directions. Such a perspective 
is given by the emerging functional profile of galectins. They form a family of tissue lectins, which are potent effectors in 
processes as diverse as adhesion, apoptosis, immune mediator release or migration. This review focuses on endogenous 
and exogenous roles of galectins in glial cells such as oligodendrocytes, astrocytes and microglia in the context of de- and 
(re)myelination and its dysregulation in MS. Evidence is arising for a cooperation among family members so that timed 
expression and/or secretion of galectins-1, -3 and -4 result in modifying developmental myelination, (neuro)inflammatory 
processes, de- and remyelination. Dissecting the mechanisms that underlie the distinct activities of galectins and identifying 
galectins as target or tool to modulate remyelination have the potential to contribute to the development of novel therapeutic 
strategies for MS.
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Introduction
Multiple sclerosis (MS) is a heterogeneous inflammatory, 
demyelinating and neurodegenerative disease of the central 
nervous system (CNS) that affects 2.5 million people world-
wide. The most common clinical form is relapsing-remitting 
MS (RR-MS, 85%). Patients endure phases of increasing 
neurological deficits followed by recovery periods. After 
some time, approximately 60% of the patients enter a phase 
that is characterized by a steady decline of neurological 
functions with or without relapse (secondary progressive 
MS, SP-MS). Neuronal loss and disease progression are 
irreversible at this phase. Primary progressive MS (PP-MS) 
affects a subset of patients (10–15%) that is characterized by 
continuous progression of the disease from its onset. Current 
treatments are disease-modifying therapies and encompass 
application of immunosuppressive or immunomodulating 
drugs that reduce the number and severity of relapses in 
RR-MS, but these interventions are ineffective in halting 
disease progression [1–3]. Hence, there is an obvious need 
to develop new therapeutic strategies for progressive MS.
Remyelination following demyelination is essential for 
axonal survival and restoration of saltatory conduction 
[4–8], and its failure is a major cause of the neurological 
deficits in MS [9–12]. Therefore, restoring remyelination 
could prove to be an effective treatment in reversing dis-
ability and halting disease progression. Toward the aim of 
designing effective therapies that induce remyelination, it 
is important to understand the biological mechanisms that 
underlie the remyelination process and to identify factors 
that prevent remyelination in MS. Remyelination fails 
despite the presence of oligodendrocyte progenitor cells 
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(OPCs) in most lesions [13–19]. This observation implies 
that either stimulating extrinsic or intrinsic factors are absent 
or that inhibitory signals are dominant [20–23]. In principle, 
this reasoning prompts to examine receptor-driven pathways 
and routes of communication between cells.
In terms of a recognition process of broad relevance, the 
abundance of glycoconjugates in the nervous system directs 
attention to considering the glycan part of glycolipids and 
glycoproteins as versatile ligand (for introduction into these 
glycan structures, please see [24–31]). In fact, the concept 
of the sugar code assigns an unsurpassed ability to store 
information to these glycans. Tissue receptors (lectins) are 
present that will ‘read’ these sugar-encoded signals, fol-
lowed by ‘translation’ into effects, eliciting a broad variety 
of post-binding activities [32–34]. This functional pairing 
does not only depend on the complementarity of the direct 
ligand(glycan)–receptor(lectin) contact but also on topologi-
cal parameters to achieve the inherently high levels of selec-
tivity and specificity, letting only certain glycoconjugates 
with distinct (cognate) glycan display become counterre-
ceptors for a tissue lectin [35, 36]. Following this reason-
ing, that is, a function of this interplay in “establishment 
of the cell–cell contacts and possibly also as mediators of 
communication between the surface and the interior of the 
cell”, and the abundance of glycoconjugates in the nerv-
ous system, extracts of the electric organ tissue of Electro-
phorus electricus proved to be the source of a lectin spe-
cific for β-galactosides that became the first member of the 
ga(lactose-binding)lectin family [37].
These galectins are special to exert activities inside and 
outside of cells by glycan- and via protein-dependent bind-
ing so that they are multifunctional [38–45]. Targeting their 
counterreceptors, forming molecular bridges between them 
in adhesion (between cells) or lattice establishment (on the 
membranes’ surface) and hereby triggering signaling fulfills 
criteria for being a versatile effector. Proceeding from work 
on individual galectins to a network analysis is teaching the 
lesson that they can be expressed at the same sites and can 
functionally cooperate [46, 47]. Thus, their study is a step to 
give meaning to the expression of certain glycans at distinct 
sites and to aberrations of the glycome related to the disease 
[48]. With focus on (re)myelination and the (immuno)patho-
physiology of MS, galectins have already attained the status 
of notable players in this context. This review first provides 
an introduction to this class of effectors and then describes 
known roles of galectins during developmental myelination, 
remyelination and in the course of MS. In this context, the 
current status of knowledge on what galectins do, particu-
larly in modulating immune responses and behavior of CNS 
glial cells, i.e., oligodendrocytes, astrocytes and microglia 
that are relevant to (re)myelination, is summarized as well 
as the relevance of galectins for MS pathology. Finally, we 
discuss how galectins, either as targets or tools, may help 
to inspire the development of novel therapeutic strategies 
to combat remyelination failure in MS and hence to halt 
disease progression.
Introduction to galectins
Galectins are a family of evolutionarily conserved proteins 
that share β-sandwich folding and a distinct sequence sig-
nature within the carbohydrate recognition domain (CRD). 
Beyond binding the canonical ligand lactose/N-acetyllac-
tosamine (Lac/LacNAc), phylogenetic diversification has 
led to a divergence of the carbohydrate-binding profiles, 
for example, studied using frontal affinity chromatography 
or glycan arrays [49–52]. In principle, glycans of glyco-
proteins such as suited N-glycan, mucin-type O-glycan or 
O-mannosylated chains or of glycolipids serve as contact 
partners. Introduction of substituents such as a sulfate group 
or a sialic acid can serve as a switch for ligand activity. Of 
note, dynamic enzymatic interconversions from a cryptic to 
an active site for docking, for example, by desialylation [53], 
or spatiotemporally regulated shifts in the glycome ensure 
flexibility in controlling the recognition potential swiftly. 
Teaming up with the ligand specificity of the galectins, pro-
tein architecture is relevant for the nature of triggered post-
binding activities, as recently highlighted by the design of 
custom-made variants of human galectins [54, 55]. Thus, 
it is important to learn about galectins’ properties in this 
respect.
As illustrated in Fig. 1, three types of protein structures 
form the set of galectins in vertebrates. Notably, non-cova-
lently associated homodimers, linker-connected heterodi-
mers and a structural chimera of a CRD with an N-terminal 
tail (consisting of non-triple-helical collagen-like repeats 
enabling self-interaction and a sequence bearing two sites 
for serine phosphorylation) facilitate to bring together 
ligands in different constellations and topological order [56]. 
The chimera-type galectin-3 (Gal-3) is thus special to build 
aggregates of different spatial order via contacts between 
CRDs or the tail, which is a substrate for various proteases 
that shorten its length and impair aggregation [57–61]. In 
summary, galectins combine target specificity with the abil-
ity to generate molecular associations at various sites of the 
cell.
As first described for galectin-1 [62], galectins are synthe-
sized in the cytosol, then reaching destinations such as the 
nucleus, diverse binding partners in the cytoplasm or glycans 
on damaged vesicle surfaces [63–66]. Overall, family members 
such as galectins-1 and -3 can thus perform multiple activities 
that depend on their cellular localization regulating cell cycle, 
survival (via binding of bcl-2) and RNA processing [67–69]. 
In addition, despite commonly lacking a secretion signal pep-
tide, galectins are secreted into the extracellular space and this 
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by non-classical pathways [70, 71] that, for example, involve 
exosomes [72–74]. Once secreted, galectins bind to matrix or 
cell surface glycoconjugates, readily bridging suited partners 
to form aggregates, and this is regulated by glycan structure, 
density and mode of presentation [75, 76]. When then in con-
tact with the cell surface, galectins can re-enter the cell, there 
handled by the trafficking machinery as elaborately as for 
export and involved in sorting basolateral and apical cargo in 
post-Golgi compartments [77, 78]. Hereby, the residence time 
of counterreceptors on the surface is intimately regulated, in 
critical dependence of the presence of cognate glycans. Under-
scoring the physiological potential of galectins, their presence 
is under strict control, and first cases have been described for 
an intimate spatiotemporal co-regulation of galectin/counter-
receptor presentation, for example, the Gal-1/ganglioside GM1 
route of communication between effector/regulatory T cells and 
in axon growth induction [79, 80]. This survey explains why it 
is likely that galectins will also be important in CNS processes.
Since galectins are also very potent regulators of (neuro)
inflammation, a dysregulation of galectins is expected to be 
associated with several neuroinflammatory diseases. Thus, 
examining the hypothesis of galectins as potent regulators of 
developmental myelination and remyelination as well as of a 
role in MS pathology is of relevance.
Role of galectins in developmental CNS 
myelination
Regulation of developmental myelination: a major 
role for neurons
Oligodendrocytes are the myelinating cells of the CNS and 
essential for saltatory conduction and axon survival [4–8]. 
They are generated from OPCs, which arise from neural 
stem cells in the subventricular zone [81]. Via the influ-
ence of a complex network of attractants and repellents 
such as semaphorins, OPCs proliferate and migrate via 
three consecutive waves throughout the developing CNS 
[82]. In addition, OPCs need the physical interaction with 
the vascular endothelium to migrate to their destination 
[83]. When having arrived at their destination and then 
subjected to local, mainly neuron-derived signals, OPCs 
start to differentiate towards mature, post-mitotic myeli-
nating oligodendrocytes. Notably, part of the OPCs persist 
in the adult brain and develop into adult OPCs, while the 
generation of OPCs from neural stem cells also contin-
ues into adulthood [81, 84, 85]. The differentiation phase 
consists of (1) establishing contact with the newly formed 
axon, (2) expressing myelin genes and generating myelin 
Fig. 1  Overview of the classification of the three types of modular 
architecture of vertebrate galectins. Proto-type galectins contain a 
single carbohydrate recognition domain (CRD) and are able to form 
monomeric or homodimeric structures. Tandem-repeat-type galec-
tins have two distinct CRDs and are covalently associated via a linker 
peptide with natural variation of linker length by alternative splicing; 
chimera-type galectin, i.e., galectin-3 harbors one CRD and a non-
lectin domain which consists of an N-terminal region and nine colla-
gen-like repeat units that are substrates for matrix metalloproteinases 
(MMP-2/-7/-9/-13) and PSA-mediated cleavage at different positions 
shown by arrows. The N-terminal region functions as a site for serine 
phosphorylation. Galectin-3 is monomeric in solution in the absence 
of a ligand and can form aggregates in contact to oligo- or polyvalent 
ligands via the N-terminal tail, the CRD, or both
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membranes and (3) enwrapping the axon and creating a 
compacted myelin sheath. OPC differentiation requires 
appropriate timing for its initiation and then follows step-
wise stages. The course of differentiation is well studied 
and defined in cultured OPCs by morphology and by the 
appearance of stage-specific lipid and protein markers 
[86–88]. Viewing such characteristics, OPCs are bipolar 
and distinguished from mature oligodendrocytes by the 
expression of platelet-derived growth factor receptor alpha 
(PDGFRα), neural/glial antigen 2 (NG2), surface gangli-
osides that are recognized by A2B5 antibody, and tran-
scription factor NK2 Homeobox 2 (Nkx2.2). Concerning 
this aspect of the proteome, oligodendrocyte lineage cells 
share the expression of the oligodendrocyte transcription 
factor 2 (Olig2) [89, 90]. Immature oligodendrocytes are 
in an intermediate status of differentiation, and here the 
expression of 2′3′-cyclic nucleotide 3′-phosphodiesterase 
(CNP), a myelin-specific protein, and glycosphingolipids 
serve as characteristics. At this stage, the cells present 
high levels of galactosylceramide (GalCer) and its deriva-
tive with 3′-O-sulfation, i.e., sulfatide, at their surface. 
However, they do not form myelin membranes yet. Mature 
oligodendrocytes then have multiple processes and gen-
erate myelin membranes, while maintaining high levels 
of sulfatide and GalCer at their surface. On the level of 
proteins, mature oligodendrocytes are characterized by 
the expression of myelin constituents, including the major 
myelin basic protein (MBP) and proteolipid protein (PLP) 
that are present in compact myelin and myelin-associated 
glycoprotein (MAG) and myelin oligodendrocyte glyco-
protein (MOG) that are present in non-compact myelin.
Both extrinsic factors and intrinsic signaling mechanisms 
that can engage transcription factors control OPC differentia-
tion. The onset of OPC differentiation at the appropriate time 
and place is explained by the “derepression” model [91]. 
Central to it, transcription factors that maintain the status are 
downregulated or they are relocalized by reducing extrinsic 
signals that constantly inhibit differentiation. This prevents 
premature OPC differentiation and allows for a tightly regu-
lated timing of OPC differentiation by stimulating factors. 
During development, inhibitory factors for OPC differen-
tiation are mainly axon derived. In fact, there are several 
means by which axons affect OPC behavior and the correct 
onset of OPC differentiation. For example, inhibitory axonal 
factors inhibit premature OPC differentiation such as Jag-
ged-1, neural cell adhesion molecule-bearing polysialic acid 
(α2,8-linked sialic acids; PSA) chains [92, 93] and LINGO-1 
(leucine-rich repeat Ig domain-containing Nogo-interacting 
protein 1) [22, 94, 95]. Besides the axonal inhibitory signals 
that determine differentiation onset, axons secrete trophic 
factors [such as PDGF, fibroblast growth factor 2 (FGF-
2), insulin-like growth factor 1 (IGF-1)] that regulate OPC 
proliferation and migration [96–98]. Myelin formation and 
OPC differentiation are promoted by the release of gluta-
mate from synaptic vesicles along axons in vitro [99–101]. It 
appears that synapses onto myelin-forming oligodendrocytes 
are not required for activity-dependent myelination. In con-
trast, myelination is regulated by non-synaptic junctions that 
signal through local intracellular calcium [102]. Glutamate 
release from active axons initiates local production of MBP 
in oligodendrocytes by the assembly of cholesterol-rich 
microdomains and induction of Fyn kinase activity [99]. In 
addition, an increase of frequency of  Ca2+ transient activ-
ity in sheaths is correlated with sheath elongation [103]. 
Interestingly, a certain oligodendrocyte is able to compart-
mentalize signals as different processes of the cell that act 
independently regarding myelin induction [102]. However, 
multiple stages are involved in the formation of myelin and 
only within a brief window of opportunity will oligodendro-
cytes generate new myelin segments [104, 105].
Next to neuronal-derived signals, communication of 
astrocytes and microglia to oligodendrocytes contributes 
to developmental myelination and myelin maintenance 
[106–108], while being even more prominently involved 
in the regulation of remyelination (see in section “Role of 
galectins in CNS remyelination”). Also, adaptive immune 
cells are involved in developmental myelination. B cells 
migrate to the developing brain and increase OPC prolif-
eration by the secretion of natural IgM antibodies [109]. 
While the molecular and cellular regulation of develop-
mental myelination has been studied extensively, insights 
into the role of the glycome and of galectins in neuronal 
function and OPC maturation herein are being gained over 
a comparatively brief period. Major steps toward defining 
galectins as parts of the machinery driving these processes 
are presented in Table 1.
Galectins in neuronal function
Initial evidence for galectin presence in neurons by haemag-
glutination assays [110–112] led to immunohistochemical 
localization [113, 114] and application of a galectin as tool 
for detecting accessible binding sites [115]. Intriguingly, lac-
toseries glycoconjugates appear available so that a functional 
pairing was hypothesized within the concept of the sugar 
code already at that time [116]. In this context, maturation of 
neurons during CNS development involves directed axonal 
growth towards the correct targets, accompanied by neurite 
branching necessary for an exploration of the environment. 
At present, galectins-1, -3 and -4 have been shown to be 
instrumental in axonal development and functioning includ-
ing its myelination. Galectin-1 is prominently expressed in 
neurons and upregulated during sensory and motor neuron 
development [117, 118]. Its presence guides primary olfac-
tory and somatosensory axons and promotes neurite sprout-
ing, both in vitro and in vivo, i.e., as shown by aberrant 
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topography of olfactory axons in Lgal1−/− mice [117, 
119–121]. Galectins-3 and -4 are transiently expressed dur-
ing development and downregulated at the onset of myelina-
tion [122–124]. Galectin-4 is present in cortical and olfac-
tory neurons [124], here required for proper axon growth and 
elongation [125]. In functional terms, neuronal galectin-4 
sorts and organizes transport of the axonal glycoprotein 
neural cell adhesion molecule L1 in a sulfatide-dependent 
manner [125]. Galectin-4, via binding to LacNAc termini of 
N-glycans, ensures proper clustering of L1 on axons in mem-
brane microdomains and spatial organization at the axonal 
surface [125]. As observed in polarized epithelial cells, neu-
ronal galectin-4 stabilizes distinct membrane microdomains 
and organizes apical protein transport of its cargo L1 [77, 
126]. Of note, in cultured hippocampal neurons, L1 binds 
to immobilized galectin-3 when phosphorylated at the ser-
ine residues in the N-terminal section, what in turn regu-
lates the segregation of L1 to discrete plasma membrane 
domains [127]. These domains recruit membrane–actin 
linkers (ERMs), which destabilize actin to stimulate local 
axon branching. In addition, extracellular immobilized 
galectin-3 promotes neurite outgrowth, but—in contrast 
to galectin-1—has no effect on axonal guidance in vitro 
[127–129]. When appropriately clustered, L1 binds to oli-
godendroglial contactin (also called F3) and activates Fyn 
kinase, which initiates MBP-specific mRNA synthesis and 
myelin biogenesis in oligodendrocytes [130–133]. In addi-
tion, axons harbor discrete galectin-4-containing domains 
that impede the deposition of myelin by oligodendrocytes 
[134]. In these myelination-excluding domains, galectin-4 
interacts with axonal contactin-1, which in myelinated axons 
is present in the non-myelinated nodes of Ranvier [134]. 
Interestingly, the sequestering of the nodal protein contac-
tin-1, the expression of neuronal galectin-4, and the size of 
the galectin-4-containing domains are independent of the 
interaction with oligodendrocytes or myelin, indicating that 
this is an intrinsic property of neurons. Hence, endogenous 
galectin-4 modulates axonal formation and outgrowth and 
it precludes myelin deposition, while exogenous galectins-1 
and -3 determine the extent and position of axon branch-
ing. Obviously, these data do not only indicate physiologi-
cal significance of individual galectins, but also substantiate 
functional cooperation so that further exploring the galectin 
network, for example, following initial data on RT-PCR sig-
nals for galectins-7 and -8 [135], is an attractive endeavor.
Galectins in oligodendrocyte maturation
In addition to the role of endogenous neuronal galectin-4 as 
a local axonal inhibitor of myelination, secreted neuronal 
galectin-4 regulates the timing of OPC differentiation and 
therefore the onset of myelination. Non-myelinated neu-
rons produce and secrete galectin-4, which then binds to 
still uncharacterized counterreceptors that transiently appear 
on primary processes of immature oligodendrocytes [124]. 
Extracellular galectin-4 binding impairs OPC differentiation 
and induces dedifferentiation and proliferation in a subset 
of cells. Both CRDs of the heterodimeric galectin that are 
associated by a linker of a length of physiological signifi-
cance [136], and the integrity of this display as tandem-
repeat-type protein are required for galectin-4-mediated 
inhibition of OPC differentiation [124]. This result suggests 
that galectin-4 may reorganize the membrane by bringing 
distinct glycoconjugates in close proximity exclusively at 
the cell surface of primary processes. Given its association 
with axonal contactin-1 [134] and that oligodendroglial F3/
contactin-1 triggers MBP expression [130, 131, 133, 137], 
it is tempting to assume that one of the galectin-4-binding 
sites on the oligodendroglia surface may be contactin-1. At 
the onset of myelination, neurons cease to secrete galectin-4, 
which creates a permissive environment for OPC matura-
tion and oligodendrocytes to myelinate the bare axons. What 
triggers the neuron to discontinue secretion of galectin-4 
remains to be determined. In other cells, this process is regu-
lated by Src family kinase-mediated phosphorylation of its C 
terminus [138]. Of relevance in this respect is that no myelin 
deficits were observed in  Src−/−,  Yes−/− or  Lyn−/− mice at 
postnatal day 28 [139]. This may be due to compensatory 
mechanisms, or, because earlier time points were not ana-
lyzed, potentially accelerated myelination is not revealed yet. 
However, Src family tyrosine kinase Fyn expression in neu-
rons and oligodendrocytes is important for myelination [140, 
141], although Fyn does not appear to be involved in the 
timing of OPC differentiation [139]. Also, Src kinase activ-
ity is upregulated in  Fyn−/− mice [142], and it is tempting to 
explore the role of neuronal Fyn/Src kinases in galectin-4 
phosphorylation in relation to its externalization.
Oligodendrocytes endogenously express, but do not 
secrete, galectin-4 in vitro. In OPCs, galectin-4 is localized 
to the cytoplasm, and, as OPCs are polarized cells [132, 
143], galectin-4 may affect trafficking of apically located 
glycoproteins and -lipids, as observed in enterocyte-like 
cells and neurons [77, 125]. This can very well include sul-
fatide, especially the fraction-bearing long-chain fatty acids. 
This galactosphingolipid, that is enriched at the oligoden-
droglial surface, acts as a negative regulator of myelination 
[144, 145], as galectin-4 does, and it is also involved in the 
timed trafficking of the major myelin protein PLP to the 
myelin membrane [146, 147]. Upon OPC differentiation, 
galectin-4 shifts from a cytoplasmic to a nuclear localization 
[124]. In the nucleus, galectin-4 regulates the expression of 
MBP by binding to the transcription factor Sp1 to activate 
p27-mediated MBP expression [148, 149]. Hence, while 
neuronal galectin-4 after secretion precludes OPC differen-
tiation, oligodendroglial galectin-4 in nuclei promotes MBP 
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expression. These observations underscore that the location 
of galectins matters conspicuously.
In addition to galectin-4, galectins-1 and -3 also modulate 
the maturation of oligodendrocytes. Galectin-3 expression, 
similar to that of galectin-4, decreases upon developmental 
myelination, the galectin-1 level instead increases upon brain 
development and is leveling off in the adult rat brain [123, 
150], our unpublished observations). In contrast, in vitro, 
galectin-1 is downregulated, whereas galectin-3 is upregu-
lated upon OPC differentiation [123]. In addition, cultured 
astrocytes and microglia harbor galectins-1 and -3. Although 
monocultures were examined, in situ hybridization studies 
that confirm endogenous galectin-specific mRNA levels in 
glial cells in vitro and in vivo are still lacking, as well as 
proof that these galectins are externalized by cells of the 
oligodendrocyte lineage will be welcome. In Lgals3−/− mice, 
MBP expression is downregulated, less axons are myelinated 
and myelin is less compact than in wild-type mice. The 
hypomyelination phenotype goes along with increased num-
ber of OPCs [151] and appears to be reflected by behavioral 
abnormalities in Lgals3−/− mice [123]. Hence, galectin-3 
plays a critical role in OPC differentiation, myelin integrity 
and function, likely via distinct biological processes. For 
example, in OPCs but not in mature oligodendrocytes, the 
N-terminal tail of galectin-3 is cleaved by matrix metallopro-
teinasae 2 (MMP-2) [123], a process shown in Fig. 1. This 
indicates that different biological functions of endogenous 
galectin-3 in OPCs and mature oligodendrocytes appear 
likely. As already noted, MMP-dependent cleavage impairs 
the N-terminal tail’s capacity toward self-aggregation [152]. 
In addition, processing may also affect secretion: a MMP-
resistant galectin-3 variant was found to be less secreted 
[70]. Of interest, glycoprotein cross-linking of galectin-3 is 
required for apical sorting of non-raft-associated proteins, 
whereas in galectin-3-depleted cells cargo is mistargeted to 
the basolateral membrane [78]. Of relevance in this respect 
is that the growing myelin membrane is served by a baso-
lateral trafficking pathway [153–155]. Therefore, galectin-3 
may participate in establishing oligodendrocyte polarity, 
its absence interfering with myelin biogenesis and com-
paction, as is observed in Lgals3−/− mice [123]. Similar to 
Lgal3−/− mice, Lgals1−/− mice have significantly less myeli-
nated axons, particularly in smaller diameter axons, while 
myelin was more loosely wrapped around axons than in 
wild-type mice [156]. Galectins-1 and -3 do not compensate 
for each other, indicating that these galectins control myelin 
integrity and compaction via distinct mechanisms. A case 
of functional antagonism between them is the inhibition of 
galectin-1-dependent neuroblastoma growth regulation by 
galectin-3 [157].
In addition to their endogenous roles, when administered 
to cell cultures, galectins-1 and -3 interfere with OPC matu-
ration. Exposure in vitro to a relatively low concentration 
of recombinant galectin-1 impairs OPC differentiation, 
whereas galectin-3 treatment at the equivalent concentration 
increases both OPC differentiation and the extent of myelin 
membrane formation [123, 158]. In contrast, a relatively 
high concentration of galectin-1, ensuring its presence as 
homodimer [159, 160], increases OPC differentiation [156]. 
Similar contrasting effects of different galectin-1 forms have 
been observed in peripheral nerve injury. Thus, the common 
homodimeric form of galectin-1 enhances degeneration of 
neuronal processes in a lectin-dependent manner, whereas 
oxidized monomeric galectin-1 that lost its capacity to bind 
sugar promotes axonal regeneration [161, 162]. The distinct 
biological functions of galectin-1 on OPC differentiation 
may depend, in addition to its concentration and timing, 
on the status of its six cysteine residue. When oxidized at 
these sites, galectin-1 loses its carbohydrate-binding activ-
ity [163–166]. Notably, when immature oligodendrocytes 
are treated with galectin-1 at a relatively low concentration, 
MMP activity is enhanced which may increase the extent 
of MMP-mediated cleavage of galectin-3, indicating the 
possibility for interplay between these galectins in OPC 
differentiation [123, 158]. Extracellular galectin-3 acceler-
ates OPC differentiation by modulating signaling pathways 
that lead to changes in actin cytoskeleton dynamics [158]. 
More specifically, in a CRD-dependent manner, galectin-3 
reduces activation of Erk1/2 and increases Akt-mediated 
β-catenin signaling, an inducer of a shift from polymerized 
to depolymerized actin. This change in the status of the actin 
cytoskeleton dynamics is known to drive oligodendrocyte 
process outgrowth and branching, what is essential to ini-
tiate myelin membrane formation [167, 168]. In addition, 
extracellular galectin-3 increases MBP expression, a process 
only partially dependent on its CRD, which emphasizes that 
galectin-3 modulates OPC differentiation via multiple means 
including protein–protein interactions via its non-lectin part 
within the chimeric structure [167].
Microglia and astrocytes are cellular sources of secreted 
galectin-3 [123]. At least in vitro, cells of the oligoden-
drocyte lineage do not secrete galectin-3 (our unpublished 
observations). The action of extracellular galectin-3 on 
oligodendrocytes thus appears to be paracrine rather than 
autocrine. During development, galectin-3 is transiently 
present in microglia, and conditioned medium of galectin-
3-deficient microglia does not promote OPC differentiation 
[123]. Oligodendroglial counterreceptors for galectin-3 
remain to be identified, but galectin-3-binding sites are 
known to be present on cell body and processes of bipo-
lar OPCs, with increasing morphology restricted to the cell 
body [158]. Of relevance, when microglia galectin-3 binds 
to IGF receptor 1 [169], a receptor that when activated on 
OPCs promotes differentiation [170–172]. Therefore, galec-
tin-3 may delay its endocytic uptake by cross-linking the 
IGF receptor on the oligodendroglial cell surface, thereby 
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potentiating IGF receptor signaling that results in enhanced 
OPC differentiation.
Taken together, both endogenous galectins and galec-
tin–glycan interactions at the cell surface drive oligodendro-
cyte maturation. Strikingly, extracellular galectins-1, -3 and 
-4 modulate OPC differentiation, rationalizing their potential 
as novel therapeutic targets and/or tools to modulate OPC 
differentiation in disease. However, as galectins-3 and -4 are 
transiently expressed during development, their roles upon 
CNS demyelination and successful remyelination need to be 
resolved to verify and/or understand the role of galectins in 
MS pathology (Table 1).
Role of galectins in CNS remyelination
Regulation of remyelination: a major role 
of microglia and astrocytes
Demyelination is the degeneration of myelin sheaths which 
in the healthy CNS is followed by a spontaneous regenera-
tive response, called remyelination. This process covers the 
regeneration of complete, newly formed myelin sheaths that 
enwrap demyelinated axons to reestablish saltatory conduc-
tion, which is salient to resolve functional deficits and to 
prevent axonal degeneration [10, 173–175]. In rodents, 
remyelination requires the generation of new mature oli-
godendrocytes from OPCs [176]. Therefore, remyelination 
morphologically resembles developmental myelination. In 
fact, some axonal factors including NCAM with its poly-
sialic acid chains (PSA-NCAM), galectin-4 and LINGO-1 
that are involved in the regulation of developmental myeli-
nation are re-expressed upon injury [20, 22, 177–179]. An 
additional level of regulatory factors, mainly provided by 
microglia and astrocytes, is required to limit inflammation 
and demyelination and to clear myelin debris. More recent 
studies also point to a direct role of the systemic environ-
ment in efficient remyelination, i.e., both circulating TGFβ 
and regulatory T cells promote OPC differentiation [180, 
181]. This distinct regulation of developmental myelination 
and remyelination is reflected in the formation of shorter and 
thinner myelin sheaths on remyelinated axons compared to 
axons that are myelinated upon development.
For successful remyelination to occur, several tightly reg-
ulated, well-timed, and distinct sequential steps as well as 
interplay between distinct types of glial cells and neurons are 
required. To study the cells and molecular factors involved in 
remyelination, animal models with global or focally induced 
demyelination have provided valuable information. Exam-
ples of these toxin-induced demyelination animal models 
are the cuprizone model, where regional demyelination is 
most prominent in the corpus callosum upon feeding cupr-
izone [182–185], and the focal lysolecithin model. Here, 
demyelination is induced by a local injection of lysolecithin 
in the brain or spinal cord white matter [184, 186, 187]. 
Importantly, lysolecithin acts also on pericytes which leads 
to disruption of the blood–brain barrier (BBB) [188], while 
in the cuprizone model the BBB remains seemingly intact 
with hardly any monocyte and T-cell infiltration and primar-
ily stimulates microglia activation [189, 190]. In fact, using 
mice that lack both T cells and B cells (Rag-1−/− mice), 
it was shown that  CD4+ and  CD8+ T cells are required for 
successful remyelination upon lysolecithin-induced demy-
elination [191], while T cells or B cells are not essential for 
cuprizone-induced de- and remyelination [192]. Studies with 
these experimental de-and remyelination models revealed 
that successful remyelination depends on OPCs adjacent to 
the injured area to be transcriptionally activated, followed by 
their proliferation and migration towards the demyelinated 
area, and subsequent differentiation of the recruited OPCs 
to mature myelinating oligodendrocytes [10]. In addition, 
microglia and astrocytes are recruited to the lesioned area 
upon toxin-induced demyelination [187, 193].
Microglia, the resident immune cells of the CNS, are one 
of the first responders upon demyelination: they initiate an 
innate inflammatory response and clear myelin debris [194]. 
Microglia responses are very heterogeneous and complex. 
Different, not yet fully defined activation states exist, of 
which the classical pro-inflammatory and alternative regen-
erative phenotype are the most studied [195–198]. Tran-
scriptomic analysis of isolated microglia at different stages 
upon cuprizone-induced demyelination shows a signature 
that supports remyelination already at the onset of demy-
elination involving, among others, phagocytosis of myelin 
debris [199]. Clearance of degenerated myelin is essential 
for remyelination, as myelin proteins are known to nega-
tively influence remyelination by inhibiting OPC differentia-
tion [200–202].
Similarly, depletion of specific microglia/macrophage 
phenotypes in toxin-induced demyelination models demon-
strates that while the pro-inflammatory phenotype is initially 
required, induction of an anti-inflammatory regenerative 
phenotype of microglia/macrophages is essential for effec-
tive remyelination [203]. To control clearance of myelin 
debris and to accomplish remyelination, bilateral cross-talk 
between microglia with other CNS (glia) cells is of utmost 
importance. Microglia promote astrocytic activation [204, 
205] and modulate OPC differentiation, while astrocytes 
instruct microglia and OPCs [106, 206, 207]. To control 
demyelination and to obtain remyelination, astrocytes play a 
dynamic and active role. They enhance the immune response 
by releasing cytokines and chemokines that recruit microglia 
to the lesion site, inhibit demyelination by releasing anti-
inflammatory cytokines and regulate myelination by tran-
siently depositing distinct extracellular matrix molecules that 
guide OPC proliferation, migration and differentiation [106, 
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107, 178, 207, 208]. Also, astrocyte ablation delays myelin 
debris clearance [193], what is required for remyelination to 
occur [200]. Also, it inhibits the regeneration of oligoden-
drocytes and myelination [193]. In analogy to microglia, 
distinct astrocyte phenotypes exist, A1 astrocytes being the 
harmful type and A2 astrocytes that upregulate neurotrophic 
factors being protective [209]. Classically (LPS) activated 
microglia, via the secretion of IL1-1α, TNF and C1q, are 
required to generate A1 astrocytes in vivo [209]. This sug-
gests a strong interplay between microglia and astrocytes 
from the onset of CNS injury onwards, concomitantly with 
the axon-derived secreted and adhesive factors.
Interplay of astrocytes and phagocytosing cells 
via galectins
As galectins are known to be involved in neuroinflamma-
tion and both endogenous and exogenous galectins modulate 
developmental myelination, the expression and function of 
galectins upon demyelinating injury and subsequent remy-
elination have been studied both in toxin-induced animal 
models and in cellular processes relevant to remyelination 
(Table 1, Fig. 2). Galectin-4 is transiently re-expressed 
on axons upon cuprizone-induced demyelination ([179], 
Fig. 2.3). Although no functional studies on the role of 
galectin-4 upon demyelination and remyelination are avail-
able, it is tempting to suggest that similar to the situation in 
CNS development re-expressed axonal galectin-4 may be 
involved in the timing of remyelination preventing prema-
ture OPC differentiation upon demyelination (Fig. 2.3a) and 
myelin deposition (Fig. 2.3b). Remarkably, and in contrast 
to developmental myelination, galectin-4 resides also in the 
nucleus of microglia/macrophages upon cuprizone-induced 
myelination ([179], Fig. 2). In vitro analysis revealed that 
galectin-4 is not secreted by microglia and macrophages 
[179]. In addition, galectin-4 protein expression is upregu-
lated in cultured alternatively activated microglia and mac-
rophages and present in both the cytoplasm and nucleus, 
suggesting that it may add to their pro-regenerative proper-
ties. In addition, galectin-4 reduces cytokine secretion of 
anti- and pro-inflammatory cytokines, IL-10 and TNFα in 
T cells [210]. On the other hand, galectin-4 administration 
to macrophages increases the secretion of TNFα and IL-10 
[211]. This indicates that in different cell types galectins 
are able to induce a distinct cytokine secretion signature, 
which may result in different pathways detrimental or sup-
porting remyelination. Of note, context-dependent effects of 
galectins reflect their ability of binding to different counter-
receptors in different cells, a hallmark of their functional 
versatility.
Functional studies to determine a role of exogenous 
galectin-1 in remyelination have been performed. Intrac-
ranial administration of galectin-1 a few days after 
lysolecithin-induced demyelination resulted in reduced 
demyelination and extensive remyelination [156]. In this 
model, galectin-1 accelerates the shift towards an alterna-
tively activated pro-regenerative microglia phenotype and 
increases the cell’s capacity to phagocytose remyelination-
inhibiting myelin debris ([156], Fig. 2.1c–e). Galectin-1 
binds with increased affinity to classically activated micro-
glia and deactivates this detrimental status by retaining the 
glycoprotein CD45 via lattice formation on the surface, 
the homodimer being ideal for cross-linking. This way, the 
phosphatase activity of CD45 is prolonged, which favors 
alternative polarization [212]. In addition, it has been sug-
gested that galectin-1 may actively promote alternative 
activation of microglia by binding to neuropilin-1 (NRP-1) 
[213]; NRP-1 ablation in microglia fails to polarize to the 
anti-inflammatory phenotype [214] and galectin-1 promotes 
axonal regeneration upon spinal cord injury by blocking the 
binding of Sema3A to NRP-1/PlexinA4 complex [215]. Next 
to galectin-1-mediated acceleration of the shift from clas-
sical to alternative microglia polarization, galectin-1 also 
directly acts on cells of the oligodendrocyte lineage upon 
lysolecithin-induced demyelination [156], Fig. 2.1a, b). 
Although the underlying mechanisms remain to be explored, 
in analogy to neurons, galectin-1 may interfere with Sema3A 
binding known to prevent OPC differentiation and remyeli-
nation [216].
Bringing astrocytes into play, microglial activation is 
controlled by astrocytes via galectin-1 secretion. In vitro 
stimulation of astrocytes by anti-inflammatory signals IL-4 
and TGFβ1 and galectin-1 itself led to an increase in the 
release of galectin-1, suggesting a positive feedback loop 
([212], Fig. 2.1f). Notably, exogenously supplied galectin-1 
reduces the astroglial response upon lysolecithin-induced 
demyelination [156]. Moreover, recombinant galectin-1 
reduces astrocyte proliferation and induces their differen-
tiation with its glycan-binding activity through the activation 
of protein tyrosine phosphatase [217]. This is accompanied 
by enhanced production of brain-derived neurotrophic fac-
tor (BDNF) [217, 218], a neuroprotective factor which is 
known to promote neuronal survival and neuronal develop-
ment (Fig. 2.1f). Upon other types of CNS injury, galec-
tin-1 is prominently expressed and secreted by astrocytes 
and enhances proliferation of neural progenitors ([219], 
Fig. 2.1g). Hereby, beneficial effects of exogenous galectin-1 
at demyelinating conditions are established, an advantage 
for considering testing the lectin for a therapeutic potential.
In addition to galectin-1, galectin-3 also exerts differ-
ent functions in the process of remyelination. For example, 
Lgals3−/− mice show a similar degree of susceptibility to 
cuprizone-induced demyelination as wild-type mice, but 
have an impaired efficiency of remyelination, as reflected by 
an increase in number of collapsed axons with defective mye-
lin wraps [151]. In more detail, OPCs in cuprizone-induced 
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Fig. 2  Schematic illustration of the cellular expression and role of 
galectins-1, -3 and -4 in the regulation of OPC differentiation upon 
successful remyelination. 1 Galectin-1 is mainly expressed and 
secreted by (reactive) astrocytes. Low galectin-1 levels (likely mainly 
monomeric) impair OPC differentiation (1a, [156], whereas high 
levels of galectin-1 (likely mainly dimeric) increase OPC differentia-
tion (1b, [158]). Galectin-1 binds to classically activated microglia 
and inhibits their polarization towards a pro-inflammatory pheno-
type (1c, [212]), accelerates the shift towards an alternatively acti-
vated pro-myelinating microglia phenotype (1d, [156]), and increases 
their capacity to phagocytose remyelination-inhibiting myelin debris 
(1e, [156]). Via a positive feedback loop [212], galectin-1 stimulates 
the release of BDNF by astrocytes (1f, [217, 218]) and enhances 
the proliferation of neural progenitors (1g, [219]). 2 Galectin-3 is 
expressed by microglia and oligodendrocyte lineage cells. Oligoden-
droglial galectin-3 is processed by MMP-2 shortening its N-terminal 
tail in OPCs, but not mature oligodendrocytes. Galectin-3 treatment 
promotes OPC differentiation (2a, [123]), may regulate astrocyte 
responses (2b, [221], favors polarization to pro-regenerative micro-
glia (2c) and increases phagocytosis of myelin debris by microglia 
(2d, [225]). 3 Galectin-4 is re-expressed by neurons and considered 
to be transiently released by axons to negatively regulate the differ-
entiation of OPCs (3a, [179]). In addition, the galectin-4-containing 
domains on axons may impede the deposition of myelin (3b, [134]). 
Upon OPC differentiation, oligodendroglial galectin-4 regulates MBP 
promoter activity (3c, [148]). Galectin-4 is present in the nucleus and/
or cytosol of microglia. The underlying mechanism(s) of action of 
galectins-1, -3 and -4 upon de-and remyelination is (are) summarized 
in Table 1
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demyelinated areas in Lgals3−/− mice are morphologically 
less complex and have a decreased ability to differentiate, 
likely due to the absence of exogenous galectin-3 to organize 
actin cytoskeletal rearrangements ([123, 167], Fig. 2.2a). In 
contrast, in another study, during cuprizone-induced demy-
elination in Lgals3−/− mice, OPC maturation is not affected 
by the loss of galectin-3 [220]. This may be related to a dif-
ference in the way the knock-out mice were generated. The 
Lgals3−/− mice that show perturbed remyelination have an 
inactivated galectin-3 gene that lacks an exon that encodes 
a part of the CRD [221, 222], while the Lgals3−/− mice that 
showed no effect on OPC maturation also lacked exons that 
are required to initiate translation and encode for the N-ter-
minal region of galectin-3 [220, 223]. Intracranial admin-
istration of MMP-processed or full-length galectin-3 in 
cuprizone-fed mice may resolve whether galectin-3 is indeed 
beneficial for remyelination. This is conceivable, as—seen 
in the cuprizone model—galectin-3 expression is increased 
and expressed in microglial cells, but not in astrocytes, and 
remains high at remyelinating conditions [199], modulat-
ing their microglial phenotype ([221], Fig. 2.2c). In addi-
tion, in cuprizone-fed Lgals3−/− mice astrocytes are more 
hypertrophic in demyelinated lesions, also suggesting a role 
for (microglia) galectin-3 in regulating astroglial responses 
upon demyelination ([221], Fig. 2.2b). The induction of tran-
sient and focal ischemic injury in Lgals3−/− revealed that 
galectin-3 is indeed required for injury-induced microglial 
activation [169]. In contrast, neonatal Lgals3−/− mice were 
protected from hypoxic–ischemic brain injury [185], indicat-
ing different means of galectin-3 to modulate microglial phe-
notype in the adult and immature brain. Another study has 
demonstrated that during cuprizone-induced demyelination 
the presence of MMP-3 is increased and that galectin-3 is 
necessary to upregulate MMP-3 expression and to promote 
microglial activation [151]. Also, and in contrast to what is 
observed upon ischemic injury [169], galectin-3-deficient 
microglia become more proliferative upon demyelination 
[151]. Of importance now is to resolve whether the actions 
of microglia-derived galectin-3 upon demyelination are 
dependent on lectin binding or its non-lectin activities.
A critical part during toxin-induced demyelination is 
clearing the remyelination-inhibiting myelin debris by resi-
dent microglia cells [200]. Galectin-3 is involved in myelin 
phagocytosis mediated by the Ras/PI3K signaling pathway 
([224, 225], Fig. 2.2d) and by regulation of the expression of 
the phagocytic receptor TREM-2b [221]. Upon demyelina-
tion in Lgals3−/−mice, TREM-2b is not detected on micro-
glia, along with the absence of the activation marker CD68. 
In addition, Lgals3−/−mice were also unable to increase 
TNFα levels upon cuprizone treatment [221], while the 
mRNA levels of chemokine CCL2, a marker for classically 
activated microglia, remained high. Altered microglia activa-
tion in Lgals3−/−mice is also reflected by increased levels of 
caspase-3 activation [221], a marker for apoptosis, in micro-
glia, indicating an anti-apoptotic role of galectin-3. While it 
is tempting to conclude that galectin-3 may favor polariza-
tion towards alternatively activated microglia, another study 
showed that the addition of galectin-3 to cultured microglia 
increased the expression of pro-inflammatory cytokines and 
enhanced the phagocytic capacities of the cells by activating 
the JAK-STAT cascade [226]. Also, galectin-3 is required 
for complete activation of TLR4 to initiate TLR4-mediated 
responses in microglia and for prolonging the inflammatory 
response [227]. This further complicates the effect of galec-
tin-3 on microglia activation and function, suggesting that a 
distinct spatiotemporal course of expression of galectin-3 is 
required for the induction of the correct microglia phenotype 
to attain successful remyelination. Worth considering, post-
translational modifications such as phosphorylation and the 
dissection of biological functions via the non-lectin part or 
CRD may help understand the molecular basis for the con-
trasting effects of galectin-3 on microglia function.
In summary, galectins-1, -3 and -4 via their interactions 
act as communication cues between neurons, astrocytes, 
microglia and OPCs and modulate cellular responses during 
de- and/or remyelination (Tables 1, 2, Fig. 2). In addition, 
intimately regulated spatiotemporal expression and secre-
tion of galectins are essential for regulating innate immune 
responses required for successful remyelination. As conse-
quence, dysregulation in galectin action may contribute to 
MS pathology. This topic will be discussed next.
Galectins in MS pathology
MS pathology: a role of peripheral and resident cells
Neurological diseases that involve myelin pathology can 
be divided into inherited or acquired disorders (reviewed 
in [228, 229]). Leukodystrophies are hereditary myelin dis-
orders that are characterized by either hypomyelination or 
demyelination. Strikingly, the primary affected cell type in 
leukodystrophies does not have to be the oligodendrocyte 
itself, i.e., the genetic defect may also cause dysfunction 
of astrocytes or microglia, emphasizing the role of other 
glial cells in myelin biogenesis. Next to genetic factors, 
viral, trauma (ischemic brain injury), toxic, metabolic and 
immune-mediated factors also play a role in the etiology 
of demyelination. MS has been known to be the archetypal 
acquired demyelinating disorder of the CNS. The cause of 
MS is unknown, although both environmental exposure and 
genetic susceptibility appear to play a role. MS is charac-
terized by inflammation, demyelination, axonal damage 
and (astro)gliosis and manifests as demyelinated lesions at 
multiple regions in the brain and spinal cord [3]. Autoreac-
tive pathogenic peripheral  CD4+ helper T cells penetrate the 
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BBB, are re-activated in brain parenchyma by CNS-associ-
ated antigen-presenting cells, and play a central role in the 
development of demyelinated lesions in RR-MS. The disease 
pathogenesis during RR-MS is driven by the fine balance 
between Th1 and Th17 cells, and their suppressive regula-
tory T cells (Tregs). These myelin-reactive peripheral cells 
cross the BBB and mediate myelin degeneration [230–234]. 
Peripheral monocyte-derived macrophages are also recruited 
to demyelinated lesions [235–237]. In active MS lesions, it 
is estimated that 55% of the macrophages arise from infil-
trated monocytes [238]. In contrast, only a few peripheral 
macrophages are present in cuprizone-induced demyelinated 
lesions [190]. Infiltrated macrophages will add microglia to 
resolve the inflamed and demyelinated area, while differen-
tial functions are apparent, microglia being more supportive 
and macrophages more immune reactive [196, 239–241]. 
Interestingly, microglia and macrophages directly commu-
nicate with each other. This has recently been shown in a 
model for spinal cord injury, where infiltrated macrophages 
reduce microglia-mediated phagocytosis and inflammatory 
responses [242]. However, it is not fully understood whether 
the infiltration of peripheral cells is a primary autoimmune 
response or a secondary response to demyelination [3, 
243–245], as primary degeneration of axons is also a charac-
teristic feature of MS [246]. In fact, de-adhesion of the inner 
loop of myelin to the axonal surface has been postulated to 
be the initial event in MS lesion formation [245, 247].
Although spontaneous remyelination occurs, most com-
monly at early stages of MS and in active lesions, a major 
cause of the neurological deficits and disease progression 
is due to incomplete or failed remyelination, particularly at 
the later progressive MS stage and in chronic lesions [9, 
10, 15, 239, 241, 243]. Remyelination is, however, observed 
in some patients at late-stage progressive MS, emphasizing 
the heterogeneity in MS pathology [3, 248, 249]. The fac-
tors involved in remyelination failure are many, including 
axonal damage, dysregulation of the cellular and molecular 
microenvironment within the lesions and/or failure of OPC 
recruitment. Strikingly, post-mortem analysis revealed that 
in approx. 70% of MS lesions OPCs are present [13, 15, 
16], indicating that extrinsic and/or intrinsic factors in MS 
lesions that allow differentiation are derailed. During the 
active phase of an MS lesion, microglia and macrophages 
are skewed towards a pro-inflammatory phenotype [250, 
251]. However, given the altered environmental factors 
in MS lesions at hand, a major subset of infiltrated mac-
rophages and resident activated microglia acquire even-
tually an intermediate activation status [252, 253]. As an 
anti-inflammatory regenerative phenotype of microglia and 
macrophages is essential for effective remyelination [203], 
dysregulated activation of microglia and/or macrophages 
may contribute to remyelination failure in MS. Also, reactive 
astrogliosis and astrocytic scar formation negatively affect 
OPC recruitment and differentiation, and thereby remyeli-
nation [254], but are on the other hand also beneficial for 
functional CNS recovery [106, 207, 255, 256].
Dysfunction of astrocytes and/or microglia, for example, 
dysregulates galectin expression and secretion, disturbs 
their interplay, leading to a molecular environment that is 
non-permissive for OPC maturation. Increased expression 
of galectins-1, -3, -4, and -9 in CNS-resident cells is appar-
ent in MS lesions compared to control white matter [257, 
258], and galectin-1 is one of the most upregulated genes in 
MS-associated microglia signature [259]. Galectins are also 
regulators of peripheral immune responses [40, 258, 260] 
and given the infiltration of peripheral cells in MS lesions, 
galectins present in the periphery may (indirectly) contribute 
to remyelination failure. Indeed, next to infiltration of mac-
rophages, infiltrating regulatory T cells have regenerative 
properties, by promoting OPC differentiation and remyeli-
nation [181], while Th17 cells decrease OPC differentiation 
and survival [261]. Therefore, before discussing whether 
an increased presence of these galectins in MS lesions is 
beneficial or detrimental to remyelination, we first describe 
whether these galectins, when present in the periphery, may 
be involved in adaptive immune responses in MS.
Galectins in MS‑related neuroinflammation
Experimental models that recapitulate all aspects of MS 
pathology are not available, in part due to the unknown 
cause, if only one, and heterogeneity in MS. While in toxin-
induced demyelination models pathogenic T cells are not 
involved in the demyelination process [191, 192], the adap-
tive immune system plays an important role in inducing 
demyelination in experimental autoimmune encephalomy-
elitis (EAE) models. Depending on the species, strain, and 
the used myelin protein/peptide, different courses, including 
acute, relapsing-remitting and chronic, can be initiated in 
EAE models [262]. The initiation and peak of the disease 
are mediated by Th1 and Th17 responses, while recovery 
from EAE is initiated by a shift towards Th2 cell responses 
[263], although another study found that Th2 cells also have 
the potential to induce EAE [264]. Furthermore, in the EAE 
model by controlling cytokine production and the movement 
of T cells, regulatory T cells have been found to be protec-
tive and mediate recovery from EAE [265, 266]. Also, as in 
MS lesions, infiltrated peripheral macrophages, as well as B 
cells, are present at the affected areas [267]. In contrast, the 
role of microglia in EAE is considered to be less important 
than in MS [243]. Therefore, the EAE model is indispensa-
ble in MS research and also exploited to elucidate the role 
of galectins in modulation of inflammatory response in the 
CNS (Table 3).
Endogenous galectin-1 expression is dynamically regu-
lated in EAE, being increased in astrocytes at the lesion 
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edges, and in subsets of  CD4+ Th1 cells and microglia before 
and at the onset of EAE symptoms, while its expression 
remains increased in astrocytes at the chronic stage [212]. 
Intravenously administration of galectin-1, either before or 
at EAE onset, results in a reduced severity of symptoms 
[268], mainly by inducing tolerogenic dendritic cells, selec-
tive elimination of pro-inflammatory Th1 and Th17 cells and 
enhanced development of Tr1 and regulatory T cells [269, 
270]. This is also shown by the inhibitory effect on T-cell 
proliferation upon binding of galectin-1 to NP-1, a glycopro-
tein counterreceptor [213, 271]. Consistently, induction of 
EAE in Lgals1−/− mice increases the severity of symptoms 
via a T helper cell response mechanism and a concomitant 
increase in classically activated microglia and axonal dam-
age [270]. Moreover, adoptive transfer of galectin-1-secret-
ing astrocytes or galectin-1-treated microglia augmented 
EAE symptoms via a mechanism that involves deactivation 
of pro-inflammatory microglia [212]. This indicates a role 
of this lectin as an anti-inflammatory mediator and neuro-
protective agent.
Lgals3−/− mice show reduced severity upon induction of 
EAE [272], a sign for a detrimental role for galectin-3 in 
EAE pathology. Interestingly, this effect is associated with a 
decreased Th17 and an increased regulatory T-cell response, 
i.e., an underlying mechanism similar as observed for 
galectin-1 administration (see above), as well as decreased 
infiltration of peripheral macrophages [272]. In contrast, a 
higher incidence and more severe course of EAE is appar-
ent in mice lacking Mgat5, an enzyme necessary for β1,6 
branching (GnT-V) on N-glycans, to which galectin-3 can 
bind, preferably when presenting LacNAc repeats. Given the 
hereby caused reduction in galectin-3 counterreceptors on 
the T-cell surface, Mgat5−/− mice displayed enhanced T-cell 
receptor (TCR) clustering and diminished polarization to 
Th2 cells, and developed spontaneous inflammatory demy-
elination and neurodegeneration [273, 274]. Similarly, ear-
lier studies have identified galectin-3 as a negative regulator 
of T-cell activation [273, 275]. By cross-linking TCRs and 
other glycoproteins on the surface of naive T cells, galectin-3 
restricts TCR clustering at the site of antigen presentation, 
which prevents T-cell activation. Thus, the role of galectin-3 
in T-cell responses in EAE is currently controversial.
Inside the CNS, galectin-3 is highly implicated in the 
pathophysiology of EAE. In EAE, galectin-3 is present 
in phagocytosing microglia and macrophages and is 
upregulated in areas of demyelination and myelin degen-
eration [276, 277]. Along with the expression of MAC-1 
(CD116), which mediates myelin phagocytosis, galectin-3 
(also known as MAC-2) is, as in the case for microglia, an 
in vivo marker for an activated phagocytosing macrophage 
[276, 278]. Interestingly, peripheral macrophages obtained 
from Lgals3−/− mice are defective to become alternatively 
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increased expression and secretory activity for endoge-
nous galectin-3 [279]. On macrophages, galectin-3 binds 
to CD98 and stimulates the PI3K pathway that drives the 
alternative activation route of macrophages [279]. Hence, 
this type of macrophage activation phenotype is dependent 
and sustained by the endogenously expressed galectin-3. 
In contrast, in vitro, enhanced secretion and expression 
of galectin-3 by classically activated human macrophages 
are observed [280]. Moreover, galectin-3 sustains a pro-
inflammatory microglia and macrophage phenotype in a 
spinal cord injury model [281]. Evidently, effects of galec-
tin-3 on phagocytosing cells are complicated, suggesting 
that a timed and context-dependent expression of galec-
tin-3 is necessary for the induction of the correct micro-
glia/macrophage phenotype. Despite the dual properties of 
galectin-3 in EAE, i.e., peripherally and at the lesion site, 
the overall impact upon demyelination in the CNS is that 
galectin-3 is instrumental in modulating the phenotype of 
macrophages at the demyelinated area.
Galectin-9, a tandem-repeat-type family member, has 
also been implicated in EAE development. Intraperitoneal 
administration of galectin-9 early after EAE induction 
results in a reduced severity, whereas siRNA-mediated 
silencing of galectin-9 results in an increased severity of 
clinical symptoms [282]. Galectin-9 is a binding partner 
for the glycoprotein Tim-3, a type-1 membrane protein 
specifically expressed on the surface of fully differentiated 
Th1 cells. Galectin-9 is a negative regulator of Th1 cell 
function and induces phosphorylation of Tim-3 which in 
turn triggers Th1 cell apoptosis, thereby shifting the bal-
ance towards Th2 cells and reducing extent of inflamma-
tion [282, 283]. Bat-3, a binding partner of intracellular 
tail of Tim-3, promotes proliferation and is a protective 
agent of Th1 cells against galectin-9-mediated cell death 
[284]. Also, reduced expression of Tim-3 on T cells has 
been suggested as an intrinsic defect that contributes to 
the pathogenesis of MS [285]. Blocking the interaction 
of galectin-9 with Tim-3 results in reduced apoptosis of 
T cells of RR-MS patients, but not in T cells obtained 
from PP-MS patients, which may relate to the upregula-
tion of Bat-3 in PP-MS [286]. Thus, the Tim-3/Galectin-9 
pathway seems to be malfunctional in PP-MS. Of note, 
when IFN-β, applied to treat RR-MS, is fused to galectin-9 
to build a conjugate, the immunosuppressive effects of 
IFN-β on Th1 cells are more effective and its side effects 
are reduced [287]. Galectin-8 that also has the tandem-
repeat-type architecture exerts similar immunosuppressive 
responses as galectin-9 does in EAE. Fittingly, EAE is 
exacerbated in Lgals8−/− mice, by modulating the bal-
ance of Th17 and Th1 cells and their Tregs [288]. This 
galectin induces apoptosis in Th17, but not Th1 cells, 
and galectin-8 administration ameliorates EAE [288]. In 
the clinical situation, the possibility for the occurrence 
of auto-antibodies against galectins should be considered 
(see below, [289, 290]).
In conclusion, galectins-1, -8 and -9 exert immunosup-
pressive and anti-inflammatory effects, and galectin-3 acts 
as a pro-inflammatory regulator. These observations strongly 
suggest that galectins-1, -3, -8 and -9 are involved in EAE/
MS pathology by modulating T-cell-mediated inflammation, 
macrophage recruitment and function at the periphery and/
or within the infiltrated lesioned areas. While the effect of 
galectin-4 in EAE pathology has not been examined, the 
ameliorating effect of sulfatide treatment on EAE (sulfa-
tide being a counterreceptor), among others via inhibition 
of T-cell proliferation, is galectin-4 dependent [291]. It is 
obviously of importance to gain further knowledge on how 
these galectins play a role in remyelination failure, which 
mainly unfolds inside the CNS, and then how this knowledge 
can be used to overcome remyelination failure in MS.
Galectins in remyelination failure
Although OPCs are recruited at the demyelinated site, an 
environment that negatively impacts OPC differentiation is 
suggested to be one of major causes of remyelination failure 
in MS [9, 10]. Why remyelination ultimately fails in MS 
is still unknown and may not be assigned to one particular 
cause, but is likely related to multiple events in different 
cells and even may differ in the different type of MS lesions. 
MS lesions can be partly remyelinated, but remyelination is 
most prominent in sites of active lesions [249, 292, 293], 
suggesting that the molecular and cellular environment is 
important for remyelination efficiency. This may include a 
beneficial role for microglia/macrophages, when appropri-
ately activated, and a detrimental role for the astrogliotic 
scar in chronic lesions [292, 294]. Given their role in remy-
elination, dysregulated galectin expression and/or function 
may contribute to remyelination failure in MS.
Galectin-1,-3, and -9 protein levels are significantly 
increased in MS lesions compared to control white matter 
[167, 258], a clear hint of the contribution to MS pathology, 
including remyelination failure. In MS lesions, galectin-1 
is mainly localized to the cytoplasm of microglia/mac-
rophages, while the number of astrocytes harboring galec-
tin-1 is decreased in astrocytes compared to control white 
matter [258]. In contrast to cuprizone-mediated demyelina-
tion, microglia/macrophages rather than astrocytes appear as 
main cellular source of galectin-1 in MS. Studied by western 
blot analysis in vitro, MS astrocytes externalize relatively 
more galectin-1 as homodimers, while normal astrocytes 
mainly secrete monomers [258]. In addition, in contrast to 
normal astrocytes, galectin-1 is localized in nuclei of MS 
astrocytes, both in vitro and in vivo [258]. This may be a 
feature of A1 astrocytes, which are observed in lesions of 
RR-MS patients [209], while their role in remyelination 
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(failure) remains to be established. Presence of galectin-1 
as homodimers may be beneficial for OPC differentiation 
when ligated to galectin-1-binding sites on OPCs [156, 295], 
while galectin-1 monomers secreted by normal astrocytes 
may prevent OPC differentiation [123]. Also, galectin-1 
deactivates classically activated microglia, thereby favor-
ing their alternative activation [212] and inducing myelin 
phagocytic capacity, both processes beneficial for OPC dif-
ferentiation [200, 203].
Galectin-3 expression is increased in active MS lesions, 
and the lectin is present in the cytoplasm of microglia/mac-
rophages and astrocytes [258]. At first glance, increased 
galectin-3 expression seems to be beneficial for OPC dif-
ferentiation, as exogenously applied galectin-3 directly pro-
motes OPC differentiation [123], and indirectly modulates 
OPC differentiation by playing a pivotal role in the switch 
towards a regenerative phenotype of microglia/macrophages 
[225, 276]. Nevertheless, although more frequently observed 
in active lesions compared to other MS lesions, complete 
remyelination fails in MS lesions. This may imply that (1) 
galectin-3 is not secreted at the lesion site, (2) exogenous 
galectin-3 is not sufficient to induce OPC differentiation, i.e., 
other local inhibitory factors may be dominant, or (3) OPCs 
and/or microglia/macrophages may lack cognate determi-
nants for galectin-3 to initiate a response.
Although not observed at the mRNA level [258], axonal 
galectin-4 is (re)-expressed in chronic MS lesions, as also 
observed in cuprizone-induced demyelination and likely 
a default response to demyelination [179]. Provided that 
axonal galectin-4 is secreted in MS lesions, galectin-4 may 
impair OPC differentiation [179]. Its presence in axons per 
se likely prevents myelination deposition [134]. In active MS 
lesions, galectin-4 was observed in the nucleus and cyto-
plasm of activated microglia/macrophages, which efficiently 
endocytose galectin-4 in vitro [179]. In this way, microglia/
macrophages may scavenge galectin-4 away from immature 
oligodendrocytes and attenuate the negative role of galec-
tin-4 on differentiation [179]. Its persistent presence in and 
potential secretion by demyelinated axons indicate that 
axonal galectin-4 in MS lesions may be a potential cause of 
remyelination failure in MS, particularly in chronic lesions 
where the number of microglia/macrophages is reduced 
[296, 297].
The role of galectins-8 and -9 in demyelination–remy-
elination models has not been thoroughly investigated yet. 
Although total galectin-8 protein expression is not enhanced, 
at the cellular level galectin-8 is abundantly present in 
microglia/macrophages in active MS lesions, while being 
absent in microglia in tissue adjacent to the lesion [258]. The 
presence of galectins-8 and -9 at the lesion site may have 
immunomodulating roles on the infiltrated T cells that are 
present in MS lesions, which may include selective apopto-
sis of Th17 and Th1 cells. Th cells and cytotoxic T cells are 
localized perivascularly, as well as being diffusely present 
throughout MS lesions [292, 298]. Galectin-9 is produced 
and secreted by activated astrocytes [299–301] and syner-
gizes with the TLR3 agonist poly(I:C) to increase TNF-α 
secretion by microglia in a Tim-3-independent manner 
[299]. Interestingly, poly(I:C)-stimulated microglia enhance 
galectin-9 expression in astrocytes, emphasizing a role for 
galectin-9 in astrocyte–microglial cross-talk. Although 
galectin-9-specific mRNA levels are increased in astrocytes 
that were isolated from MS lesions [257], enhanced pro-
tein expression of galectin-9 in MS lesions is related to its 
presence in microglia/macrophages rather than astrocytes 
[258]. Remarkably, galectin-9 is mainly present in microglia/
macrophage nuclei in active lesions, while in chronic active 
MS lesions galectin-9 exclusively localizes to the cytosol 
[258]. This nuclear-to-cytoplasmic relocation may reflect 
changes in galectin-9 function, as respective shuttling of 
galectin-3 is known to exert [66]. A potential role of endog-
enous galectin-9 in microglia/macrophages polarization and 
secretion of galectin-9 by microglia/macrophages remain to 
be determined. Notably, galectin-9 levels are higher in CSF 
of SP-MS patients than in CSF of RR-MS patients, which 
is likely a reflection of innate rather than adaptive immune 
responses [302]. This indicates that galectin-9 is involved in 
the pathophysiology of SP-MS, and given its role in inter-
glial communication, may contribute to remyelination fail-
ure by retaining or inducing a pro-inflammatory microglia/
macrophage phenotype.
In summary, galectins-1,-3, -4, -8 and -9 may contribute 
to remyelination failure in MS lesions. Although several 
questions remain open on the contribution of galectins to 
remyelination failure, the fact that several galectins appear 
to be involved in successful remyelination combined with 
the derailed regulation of galectins in MS lesions, investing 
further efforts to delineate, if possible, a therapeutic poten-
tial appears to be warranted.
Galectins: novel targets or tools to overcome 
remyelination failure in MS?
A favored strategy to overcome remyelination failure in 
MS is to promote OPC differentiation. Several compounds, 
including benztropine, are known to promote remyelination 
in vivo after cuprizone treatment by direct antagonism of 
receptors [303]. Although these compounds are very effec-
tive in promoting OPC differentiation (reviewed in [304]), 
OPCs in MS lesions usually face cellular and molecular 
environments that inhibit their differentiation. Given the 
multifaceted actions of galectins in interglial communi-
cation, there are several hurdles that have to be overcome 
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before considering modifying therapies that are based on the 
gain or loss of (extracellular) galectin function.
The first is to define whether galectins may be useful to 
overcome remyelination failure, also taking into account 
the context of the cellular environment in the distinct MS 
lesions. Galectins-1 and -3 act as modulators of microglia 
and macrophage activation and phenotype, driving the onset 
of remyelination. In addition, galectins-1 and -3 enhance, 
whereas galectin-4 impairs OPC differentiation. Therefore, 
in active MS lesions, where microglia and macrophages are 
evenly distributed throughout the lesion, galectins-1 and 
-3 may help to skew the intermediate phenotype microglia 
and macrophages towards an anti-inflammatory phenotype 
and increase phagocytic capacity [156, 212, 279]. Micro-
glia and macrophages are hardly present in chronic inactive 
MS lesions, while their presence is limited to (parts of) the 
lesion border of chronic active lesions [249, 292]. Therefore, 
targeted delivery of these galectins may promote OPC dif-
ferentiation in chronic lesions. However, in chronic lesions 
galectin-4 is also abundantly present, in addition to many 
other negative regulators of OPC differentiation. Hence, it 
is essential to critically assess whether galectins-1 and -3 
can overcome remyelination failure in a MS lesion environ-
ment, and to verify whether a specific galectin-4 antagonist 
such as a high-affinity sulfatide derivative or a neutralizing 
antibody against galectin-4 counteracts its inhibiting effect 
on OPC differentiation.
A second hurdle to be cleared is that the biochemi-
cal nature of the binding sites of galectins-1, -3, and 4 on 
microglia, macrophages, astrocytes, and cells of the oligo-
dendrocyte lineage is not known yet. Identification of their 
counterreceptors, e.g., being a protein and/or a glycosphin-
golipid, will provide useful information about the chain of 
events toward effects. Equally important, although the activ-
ity profiles of galectins-1 and -3 appear to be similar, these 
galectins are not redundant and can likely act via different 
mechanisms at different sites, as they do not compensate for 
each other in experimental models. Therefore, it is of utmost 
importance to define the biochemical nature of counterrecep-
tors for galectins, in the case of galectin-1 especially for both 
forms. Notably, the glycosylation signature of the putative 
galectin counterreceptors(s) may alter during development 
and in different phases of de- and remyelination, and may 
thus be only transiently suited for the galectin. How access 
to the termini of N-glycans of the α5β1-integrin is regulated 
via α2,6-sialylation and sialic acid biosynthesis as crucial 
molecular switches to enable galectin-1-dependent anoikis 
induction by the tumor suppressor  p16INK4a as master factor 
provides a salient lesson for such mechanisms [305]. Indeed, 
glycosylation is subject to dynamic regulation, which defi-
nitely influences the extent of lattice formation by galectins 
[306]. Respective molecular switches with clinically relevant 
implications have been disclosed in the case of Tn sialylation 
by ST6GalNAc2 that blocks production of O-glycan core 1/2 
counterreceptors for galectin-3 and hereby attenuates breast 
cancer metastasis [307] and in the case of prostate cancer 
progression, in which O-glycan core 2 presence and sus-
ceptibility to galectin-1 and sialylated core 1 presence and 
binding to galectin-4 let the clinical course go in opposite 
directions [308–310]. Also, oligodendroglial counterrecep-
tors for galectins-3 and -4 are transiently expressed and 
spatially distributed at the surface [123, 124]. Identification 
of binding sites of galectins will also provide information 
whether these surface receptors are present in MS lesions 
and can thus be targeted by galectins when applied as a tool. 
As indicated above for the sialylation status of N-glycans and 
also known for enzymatic conversion among gangliosides, 
i.e., GD1a to GM1, or the shift from core 1 to core 2 O-gly-
cans, the glycosylation status of glycoconjugates influences 
avidity of galectins binding, and disease-related changes in 
glycosylation may prevent galectin binding. Environmental 
and genetic factors are shown to dysregulate N-glycosylation 
by Golgi-localized enzymes that could lead to inflammatory 
demyelination and neurodegeneration in MS [311]. Finally, 
as the same galectin has multifaceted roles in different cells 
at different stages of the remyelination process, knowing 
the identity of the counterreceptor(s) will allow for more 
specific understanding of post-binding effects.
Galectins are potent modulators of peripherally immune 
responses and in this way may affect the clinical course of 
MS [268, 269, 272, 282, 288]. Hence, a third hurdle is that 
targeted delivery of galectins or their agonists/antagonists to 
MS lesions is required. For example, modulation of galec-
tin levels may be accomplished by their local secretion at 
the lesion area from engineered nanocarriers and exosomes 
that pass the BBB. Also, it is essential to determine their 
effect on axons and astrocytes in the demyelinated areas. For 
example, galectin-1 dimers induce neuronal degeneration 
[162] and promote astrocyte differentiation [217]. On the 
other hand, the anti-inflammatory properties of galectin-1 
may overcome the effect of infiltrated T cells [312, 313]. In 
addition, the heterogeneity and region-specific differences 
in microglia, astrocytes and OPCs in, for example, gray and 
white matter areas also need to be considered, as well as that 
timely expression of several galectins is crucial for proper 
remyelination. Hence, targeting galectin–glycan interactions 
may represent a new therapeutic approach for promoting 
remyelination in MS lesions, provided that a comprehensive 
analysis on their effect on all lesion-resident cells has been 
performed.
Having emphasized the importance of the protein archi-
tecture for activity (Fig.  1), it is noteworthy that alter-
ing protein design is a means to generate new classes of 
galectin-based effectors, to block or to induce activities 
with clinical benefit. Galectin-3, for example, can become 
a cross-linking homodimer like galectin-1, and galectin-1 a 
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galectin-3-like chimera-type protein [314]. This special type 
of variant of galectin-1, monomeric in solution in contrast to 
the galectin-1 homodimer, has been shown to serve as func-
tional antagonist of the wild-type protein [55]. The CRDs of 
galectins-3 and -4, here especially the N-terminal unit, may 
likewise serve as galectin-based means to saturate counter-
receptors and hereby preclude triggering of harmful effects 
by the physiologically present galectin. Due to the high tar-
get specificity for glycoconjugates of each domain that they 
share with the wild-type proteins, this engineered type of 
reagent will likely be preferable to sugar-based inhibitors. 
Concerning galectin blocking, another means is specific 
(auto)antibodies, briefly referred to above.
Autoantibodies against galectins in MS
Autoantibodies against galectins may play an important 
role in the onset or progression of immune diseases [315, 
316], and the presence of autoantibodies could contribute 
to a continuous immune dysregulation in MS. Further-
more, autoantibodies against galectins may be a possible 
therapeutic target to treat MS [288, 289, 317], while on the 
other hand autoantibodies may also interfere with the action 
of galectins when therapeutically applied. A recent study 
found that sera from SP-MS patients contain autoantibod-
ies against galectin-3, which may serve as a biomarker for 
SP-MS [317]. Anti-galectin-3 antibody binding to galectin-3 
at the surface of human brain microvascular endothelial cells 
increases, among others, the expression of ICAM-1 on brain 
endothelial cells. This contributes to the disturbance of BBB 
integrity, resulting in leukocyte leakage to the CNS [317]. 
Interestingly, fingolimod, an oral sphingosine-1-phosphate-
receptor modulator used for treatment of RR-MS, leads to 
reduced level of infiltration of aggressive lymphocytes and 
was suggested to prevent endothelial cell activation induced 
by anti-galectin-3 antibodies [317]. Similarly, when admin-
istered at the time of EAE immunization, the FDA-approved 
drug for MS, glatiramer acetate (copolymer 1) reduces 
galectin-3 expression on macrophages at the lesion area 
[276]. Anti-galectin-8 antibodies have also been detected in 
sera and CSF of RR-MS patients: these proteins neutralize 
the immunosuppressive role of galectin-8 [288] and may 
thus worsen relapses. Hence, anti-galectin-8 antibodies may 
hold promise as a potential early prognostic marker. In addi-
tion, levels of autoantibodies against galectin-1 were signifi-
cantly higher in sera from MS patients [289], and it would be 
interesting to determine whether these antibodies contribute 
to disease pathology.
Hence, the presence of anti-galectin autoantibodies in 
the clinical situation in situ introduces a further level to 
be considered, their presence and significance warranting 
further efforts. In addition, anti-galectin autoantibodies 
may serve as a (prognostic) biomarker of disease progres-
sion. However, their presence may be a complicating fac-
tor when targeting galectin–glycan interactions to promote 
remyelination in MS lesions.
Concluding remarks
Why remyelination ultimately fails in MS is still unknown. 
This review provides a survey of galectin involvement 
and reflects the multifunctionality of these tissue lectins. 
Indeed, galectins have multifaceted functions in modulat-
ing innate and adaptive immune responses in MS and are 
actively involved in regulating successful remyelination 
by affecting OPC differentiation in a direct and indirect 
manner. Galectins-1, -3 and -4 can be considered as factors 
that determine OPC differentiation and thereby (re)myeli-
nation by placing glial communication in the right time 
and spatial context. Identifying the biochemical nature 
of the counterreceptors and the chain of post-binding 
events as well as the antagonism/synergy between galec-
tins in situ are open issues that need to be resolved. Also, 
a role of galectins that so far have not been investigated 
in the context of remyelination needs to be considered. 
For example, galectin-2, acting via the TLR4 pathway, 
skews macrophages toward a pro-inflammatory phenotype 
[318], which may also be valid in MS lesions. Interest-
ingly, proto-type galectins-1, -2 and -7 induce apoptosis in 
activated T cells via different profiles of caspase activation 
[319]. In addition, involvement of members of other lectin 
families such as myelin-associated glycoprotein (siglec-4) 
could be worth exploring [320], and this on the network 
level considering various emerging modes of functional 
cooperation [321]. Altogether, the evidence and consid-
erations presented in this review emphasize that dynamic 
expression, secretion and re-uptake of galectins, all in an 
intimately regulated manner, are crucial for remyelina-
tion to take place. Further research is definitely needed 
to understand the mechanisms that control the proper-
ties of galectins and their effect on OPC differentiation, 
astrocytes, microglia/macrophage activation, neurodegen-
eration and T cells. Thus, galectins do have potential as 
target or tool for the development of remyelination-based 
therapies in MS, but more work at the basic science level 
is required prior to attempting to realize their potential.
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